• Evaxion reported sustained responses without tumor progression at three-year follow-up in all evaluated advanced melanoma patients receiving personalized cancer vaccine EVX-01.
• Patients received EVX-01 alone during the third treatment year, extending clinical benefits previously reported at two-year follow-up.
• New clinical and immune findings will be presented October 24, 2026, at the ESMO Congress in Madrid.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Evaxion A/S published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202610190300PRIMZONEFULLFEED1001278581) on October 19, 2026, and is solely responsible for the information contained therein.